WO2004060280A3 - Methods and compositions for inhibiting the growth of hematopoietic malignant cells - Google Patents

Methods and compositions for inhibiting the growth of hematopoietic malignant cells Download PDF

Info

Publication number
WO2004060280A3
WO2004060280A3 PCT/US2003/039225 US0339225W WO2004060280A3 WO 2004060280 A3 WO2004060280 A3 WO 2004060280A3 US 0339225 W US0339225 W US 0339225W WO 2004060280 A3 WO2004060280 A3 WO 2004060280A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth
malignant cells
methods
hematopoietic malignant
hematopoietic
Prior art date
Application number
PCT/US2003/039225
Other languages
French (fr)
Other versions
WO2004060280A2 (en
Inventor
Ginette Serrero
Original Assignee
A & G Pharmaceuticals Inc
Ginette Serrero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & G Pharmaceuticals Inc, Ginette Serrero filed Critical A & G Pharmaceuticals Inc
Priority to AU2003296432A priority Critical patent/AU2003296432A1/en
Publication of WO2004060280A2 publication Critical patent/WO2004060280A2/en
Publication of WO2004060280A3 publication Critical patent/WO2004060280A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.
PCT/US2003/039225 2002-12-18 2003-12-11 Methods and compositions for inhibiting the growth of hematopoietic malignant cells WO2004060280A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003296432A AU2003296432A1 (en) 2002-12-18 2003-12-11 Methods and compositions for inhibiting the growth of hematopoietic malignant cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/321,587 2002-12-18
US10/321,587 US20030215445A1 (en) 1997-05-23 2002-12-18 Methods and compositions for inhibiting the growth of hematopoietic malignant cells

Publications (2)

Publication Number Publication Date
WO2004060280A2 WO2004060280A2 (en) 2004-07-22
WO2004060280A3 true WO2004060280A3 (en) 2005-06-16

Family

ID=32710755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039225 WO2004060280A2 (en) 2002-12-18 2003-12-11 Methods and compositions for inhibiting the growth of hematopoietic malignant cells

Country Status (3)

Country Link
US (3) US20030215445A1 (en)
AU (1) AU2003296432A1 (en)
WO (1) WO2004060280A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
FR2772047B1 (en) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
EP1117762A4 (en) 1998-09-29 2004-02-25 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003297217B2 (en) * 2003-02-26 2010-01-07 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of B cells
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
ES2426916T3 (en) * 2003-08-01 2013-10-25 A & G Pharmaceutical, Inc. Compositions and procedures to restore sensitivity to treatment with HER2 antagonists
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
CN104204192A (en) 2012-02-13 2014-12-10 加米达细胞有限公司 Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9443797B2 (en) * 2012-09-14 2016-09-13 STATS ChipPAC Pte. Ltd. Semiconductor device having wire studs as vertical interconnect in FO-WLP

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5416192A (en) 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
AU1325792A (en) 1992-02-03 1993-09-01 Samuel Solomon Granulins from leukocytes
JPH09506250A (en) 1993-11-23 1997-06-24 ジェネンテク，インコーポレイテッド Protein tyrosine kinase named Rse
HUT74276A (en) 1993-11-30 1996-11-28 Lxr Biotechnology Inc Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6720159B1 (en) 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US8512960B2 (en) 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US7091047B2 (en) 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
AU760466B2 (en) 1999-02-26 2003-05-15 Johns Hopkins University, The A novel inhibitor of programmed cell death
WO2001064712A1 (en) 2000-02-28 2001-09-07 The Regents Of The University Of California Methods for detection and treatment of neural cancers
DK1318837T3 (en) * 2000-08-11 2005-01-10 Wyeth Corp Method of treating estrogen receptor positive carcinoma
CA2425643A1 (en) 2000-10-11 2002-04-18 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US7411045B2 (en) 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003297217B2 (en) 2003-02-26 2010-01-07 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of B cells
US20050175616A1 (en) 2003-05-30 2005-08-11 Peter Kiener PCDGF receptor antibodies and methods of use thereof
EP1644038A2 (en) 2003-06-23 2006-04-12 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
WO2005009217A2 (en) 2003-07-21 2005-02-03 Medimmune, Inc. Diagnosis of pre-cancerous conditions using pcdgf agents
ES2426916T3 (en) 2003-08-01 2013-10-25 A & G Pharmaceutical, Inc. Compositions and procedures to restore sensitivity to treatment with HER2 antagonists
KR20070090156A (en) 2004-10-13 2007-09-05 에이 앤드 지 파마슈티컬즈, 인코포레이티드 Autocrine growth factor receptors and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIAU ET AL.: "Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption", CANCER RES., vol. 60, no. 5, 1 March 2000 (2000-03-01), pages 1353 - 1360, XP002963369 *
LU ET AL.: "Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF c DNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 8, 11 April 2000 (2000-04-11), pages 3993 - 3998, XP002963204 *

Also Published As

Publication number Publication date
AU2003296432A1 (en) 2004-07-29
US8911950B2 (en) 2014-12-16
US20120087918A1 (en) 2012-04-12
AU2003296432A8 (en) 2004-07-29
US8007997B2 (en) 2011-08-30
WO2004060280A2 (en) 2004-07-22
US20030215445A1 (en) 2003-11-20
US20100021475A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2004060280A3 (en) Methods and compositions for inhibiting the growth of hematopoietic malignant cells
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
EP1878725A3 (en) Pyrimidine derivatives and their use as CB2 modulators
WO2008063382A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2005003168A3 (en) Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
WO2003057838A3 (en) Antibodies against the muc18 antigen
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
HK1073660A1 (en) Methods and compositions and rna interference
CA2492804A1 (en) Novel inhibitors of kinases
WO2002028905A3 (en) Human anti-cd40 antibodies
BRPI0413119A (en) use of optimized adcc antibodies to treat debilitated patients
EP0954334A4 (en) Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
PT1147103E (en) FENANTRIDINE-N-OXIDES WITH PDE-IV INHIBITORS ACTIVITY
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators
WO2005062957A3 (en) Compositions and methods for combined therapy of disease
WO2007056331A3 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2004016215A3 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
WO2001005353A3 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
PL1687014T3 (en) Use of additionally fermented distillers grains for preventing and/or treating increased blood sugar values
WO2002043648A3 (en) Compounds active at the glucocorticoid receptor ii
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
WO2001059155A3 (en) Interferon-alpha induced genes
WO2004027026A3 (en) Improved methods for preparing highly active april ligand polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP